摘要:
An MRI contrast agent enables direct detection and imaging of exfoliated vascular endothelial sites. The MRI contrast agent includes an imaging unit which contains an unpaired electron-carrying atom and/or molecule and is capable of amplifying or reducing MRI signals, and a detection unit which is bonded to the imaging unit and is capable of selectively recognizing exfoliated vascular endothelial sites and binding thereto. The detection unit is exemplified by one having a chemical structure expressed by the following formula (I), wherein at least one of R1-R11 is, for example, a sulfonic acid group, and X is, for example, a phenyl group which may be substituted:
摘要:
Disclosed is an MRI contrast agent which enables direct detection and imaging of exfoliated vascular endothelial sites. The MRI contrast agent comprises an imaging unit which contains an unpaired electron-carrying atom and/or molecule and is capable of amplifying or reducing MRI signals, and a detection unit which is bonded to said imaging unit and is capable of selectively recognizing exfoliated vascular endothelial sites and binding thereto. The detection unit is exemplified by one having a chemical structure expressed by the following formula (I), wherein at least one of R1-R11 is, for example, sulfonic acid group, and X is, for example, a phenyl group which may be substituted:
摘要:
When a user designates a treatment range on a diagnostic image, a switch (12) selects a transmitter for treatment (16). Ultrasound with intensity for treatment is thereby transmitted from a probe (10) to the inside of an organism. When the treatment operation continues for a prescribed time, a control unit (18) controls the switch (12) to select a transmitter for diagnosis (14). The probe (10) thereby emits an ultrasound beam for diagnosis, senses an echo thereof, generates a diagnostic image, and carries out an inspection of a positional shift of the site to be treated. In the inspection, the control unit (18) compares the diagnostic image with a reference image, and if a significant difference is detected therebetween, determines that a shift has occurred, issues an alarm, and urges the user to correct the positional shift. It is possible to resume the treatment when the positional shift has been corrected.
摘要:
The object of the present invention is to provide a method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease.The object is achieved by the method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease comprising Step (1) of measuring the intracellular SmgGDS expression level of a patient suffering from a cardiovascular disease before and after administration of statin; and Step (2) of determining the type and/or the dose of statin for the patient in reference to the SmgGDS expression level measured in the Step (1).
摘要:
When a user designates a treatment range on a diagnostic image, a switch (12) selects a transmitter for treatment (16). Ultrasound with intensity for treatment is thereby transmitted from a probe (10) to the inside of an organism. When the treatment operation continues for a prescribed time, a control unit (18) controls the switch (12) to select a transmitter for diagnosis (14). The probe (10) thereby emits an ultrasound beam for diagnosis, senses an echo thereof, generates a diagnostic image, and carries out an inspection of a positional shift of the site to be treated. In the inspection, the control unit (18) compares the diagnostic image with a reference image, and if a significant difference is detected therebetween, determines that a shift has occurred, issues an alarm, and urges the user to correct the positional shift. It is possible to resume the treatment when the positional shift has been corrected.
摘要:
An agent and composition for the prevention of and/or treatment for vasospasm accompanying a bypass operation, which contains as an active ingredient either a compound represented by the following general formula (I) or an acid addition salt or hydrate thereof. R1 represents a hydrogen atom or a hydroxyl group.
摘要翻译:用于预防和/或治疗伴随旁路手术的血管痉挛的药剂和组合物,其包含作为活性成分的由以下通式(I)表示的化合物或其酸加成盐或其水合物。 R 1表示氢原子或羟基。
摘要:
An optical fiber is provided which has good laser beam condensation efficiency and is highly resilient, and a shockwave generating device employing same. An optical fiber is employed in an underwater shockwave generating device which projects a laser beam underwater and generates an underwater shockwave. The optical fiber includes a main body part, and a laser convergence part that is disposed upon a leading end thereof. The laser convergence part is configured so as to exhibit an approximately frustum shape wherein the diameter of the leading end is narrower than the diameter of the base end, and such that an interior angle with respect to a radial direction of a lateral face of an axial cross-section gradually decreases toward the front thereof.
摘要:
Provided are an optical fiber which has good laser beam condensation efficiency and is highly resilient, and a shockwave generating device employing same. An optical fiber (11) is employed in an underwater shockwave generating device (10) which projects a laser beam underwater and generates an underwater shockwave. The optical fiber (11) comprises: a main body part (16); and a laser convergence part (17) which is disposed upon a leading end thereof. The laser convergence part (17) is configured so as to exhibit an approximately frustum shape wherein the diameter of the leading end (18a) is narrower than the diameter of the base end (18b), and such that an interior angle θ with respect to a radial direction of a lateral face, of an axial cross-section gradually decreases toward the front thereof.
摘要:
The object of the present invention is to provide a method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease.The object is achieved by the method of determining the dose and/or administration of statins to a patient suffering from a cardiovascular disease comprising Step (1) of measuring the intracellular SmgGDS expression level of a patient suffering from a cardiovascular disease before and after administration of statin; and Step (2) of determining the type and/or the dose of statin for the patient in reference to the SmgGDS expression level measured in the Step (1).